Taysha Gene Therapies (TSHA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Jefferies, BofA Securities, Piper Sandler and Barclays are acting as joint book-running managers for the proposed offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Positive Developments and Strategic Moves Position Taysha Gene Therapies for Success with TSHA-102
- Taysha Gene Therapies price target raised to $9 from $8 at Canaccord
- Taysha Gene Therapies: Promising FDA Alignment and Strong Financials Justify Buy Rating
- Taysha Gene Therapies Advances in Rett Syndrome Trials
- Taysha Gene Therapies’ Positive Q1 2025 Earnings Call